Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurence Collette

Showing results (11-20 of 155) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapyLaurence Collette, Urs E Studer
BJU International|August 24, 2006
What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?Cora N Sternberg, Laurence Collette
Urologic Oncology|November 11, 2010
What can be concluded from the ERSPC and PLCO trial data?Urs E Studer, Laurence Collette
European Urology|November 23, 2006
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancerMassimo Maffezzini, Alberto Bossi, Laurence Collette
Critical Reviews in Oncology/Hematology|August 23, 2002
EORTC prostate cancer trials: what have we learnt?Theo M de Reijke, Laurence Collette
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!Laurence Collette, Marc Buyse, Tomasz Burzykowski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2017
Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer OutcomesXavier Paoletti, Damien Drubay, Laurence Collette
Contemporary Clinical Trials Communications|February 15, 2020
Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studiesDamien Drubay, Laurence Collette, Xavier Paoletti
European Urology|January 26, 2010
Can radical prostatectomy benefit patients despite the presence of regional metastases?Urs E Studer, Laurence Collette, Richard Sylvester
European Journal of Cancer (Oxford, England : 1990)|May 30, 2006
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trialsLaurence Collette, Tomasz Burzykowski, Fritz H Schröder
Pageof 16

Showing results (11-20 of 155) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapyLaurence Collette, Urs E Studer
BJU International|August 24, 2006
What has been learned from meta-analyses of neoadjuvant and adjuvant chemotherapy in bladder cancer?Cora N Sternberg, Laurence Collette
Urologic Oncology|November 11, 2010
What can be concluded from the ERSPC and PLCO trial data?Urs E Studer, Laurence Collette
European Urology|November 23, 2006
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancerMassimo Maffezzini, Alberto Bossi, Laurence Collette
Critical Reviews in Oncology/Hematology|August 23, 2002
EORTC prostate cancer trials: what have we learnt?Theo M de Reijke, Laurence Collette
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2007
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!Laurence Collette, Marc Buyse, Tomasz Burzykowski
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2017
Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer OutcomesXavier Paoletti, Damien Drubay, Laurence Collette
Contemporary Clinical Trials Communications|February 15, 2020
Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studiesDamien Drubay, Laurence Collette, Xavier Paoletti
European Urology|January 26, 2010
Can radical prostatectomy benefit patients despite the presence of regional metastases?Urs E Studer, Laurence Collette, Richard Sylvester
European Journal of Cancer (Oxford, England : 1990)|May 30, 2006
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trialsLaurence Collette, Tomasz Burzykowski, Fritz H Schröder
Pageof 16